Wedica (Trelagliptin ) 50mg and 100mg
0.00$
Wedica is a dipeptidyl peptidase-IV (DPP-4) inhibitor that is taken once weekly. It works by selectively and consistently inhibiting DPP-4, an enzyme responsible for deactivating incretin hormones such as glucagon-like peptide-1 and glucagon-dependent insulinotropic polypeptide. These hormones are essential for regulating blood glucose levels. By blocking DPP-4, Wedica helps increase insulin secretion in response to blood glucose levels, effectively managing blood sugar. It is supplied in tablet form for oral use.
Indications:
Trelagliptin serves as an adjunct to diet and exercise for enhancing glycemic control in adults diagnosed with type 2 diabetes mellitus. It is a highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor primarily utilized as an additional therapy when initial treatment with metformin fails to achieve the desired glycemic targets. However, it is also sanctioned for first-line use in cases where metformin cannot be administered.
Pharmacology:
The medication operates by selectively and persistently inhibiting DPP-4, an enzyme responsible for deactivating incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucagon-dependent insulinotropic polypeptide. These incretin hormones are crucial in regulating blood glucose levels. By impeding DPP-4 activity, Trelagliptin elevates GLP-1 and insulin secretion in response to blood glucose levels, thereby helping to control blood sugar levels.
Dosage & Administration:
In adults, a weekly oral dose of 100 mg of Trelagliptin is recommended. This regimen has been found to result in fewer hypoglycemic events and is 4 to 12 times more potent than Alogliptin and Sitagliptin. Administration should be in accordance with the advice of a healthcare professional.
Interaction:
Caution is advised when combining Wedica with other diabetes medications, as this may increase the risk of hypoglycemia.
Precautions and warnings:
Special precautions should be taken in patients with moderate kidney disease, hypoadrenalism, hypopituitarism, malnutrition, irregular eating habits, starvation, or those engaging in vigorous exercise. Hypoglycemia may occur when Wedica is used concurrently with other diabetes medications.
Side Effects:
Common side effects of Wedica include hypoglycemia, nasopharyngitis, and elevated lipase levels. Rare but serious adverse reactions may include acute pancreatitis, intestinal obstruction, atrial fibrillation, and elevated liver enzymes.
Overdose Effects:
There is limited information on the effects of Wedica overdose. Monitoring and appropriate supportive measures should be implemented if an overdose occurs.
Product Name | Wedica |
---|---|
Generic Name | Trelagliptin Succinate |
Formulation | Tablet |
Available size | 2×10 ’s and 2×8’s |
Strengths | 50mg and 100mg |
Reviews
There are no reviews yet.